A prospective study of inflammation markers and endometrial cancer risk in postmenopausal hormone nonusers.

Division of Biostatistics, Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Cancer Epidemiology Biomarkers &amp Prevention (Impact Factor: 4.56). 03/2011; 20(5):971-7. DOI: 10.1158/1055-9965.EPI-10-1222
Source: PubMed

ABSTRACT It is hypothesized that inflammation may mediate the relationship between obesity and endometrial cancer risk. We examined the associations of three inflammation markers, C-reactive protein (CRP), interleukin (IL)-6 and tumor necrosis factor (TNF)-α, with risk of endometrial cancer.
A case-cohort study was nested within the Women's Health Initiative, a cohort of postmenopausal women. Baseline plasma samples of 151 incident endometrial cancer cases and 301 subcohort subjects not using hormones were assayed.
CRP, but not IL-6 or TNF-α, was positively associated with endometrial cancer risk after adjusting for age and BMI [HR comparing extreme quartiles (HR q(4)-q(1)) = 2.29; 95% CI = 1.13-4.65; P(trend) = 0.012). After additional adjustment for estradiol and insulin, this association was attenuated (HRq(4)-q(1) = 1.70; 95% CI = 0.78-3.68; P(trend) = 0.127). Obesity (BMI ≥ 30 kg/m(2)) was associated with endometrial cancer risk in an age-adjusted model. The obesity effect was reduced by 48%, 67%, and 77% when either estradiol, CRP, or insulin, respectively, was included in the model, and it became null when all three factors were adjusted for simultaneously.
The association between inflammation, as indicated by a relatively high level of CRP, and endometrial cancer risk may partially be explained by hyperinsulinemia and elevated estradiol. Nevertheless, all three factors contribute to and mediate the link between obesity and endometrial cancer in postmenopausal women not using hormones.
The association between obesity and endometrial cancer risk in postmenopausal women may be attributed to inflammation, insulin resistance, and elevated estrogen.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Chronic inflammation may be important in endometrial cancer etiology. Several established endometrial cancer risk factors, particularly obesity, are hypothesized to operate through this pathway by increasing proinflammatory cytokines such as tumor necrosis factor α (TNF-α), interleukin-6 (IL-6), and acute-phase protein C-reactive protein (CRP). This study sought to investigate the association between inflammatory markers and the risk of endometrial cancer (types I and II). We recruited 519 incident endometrial cancer cases and 964 frequency age-matched controls in this population-based case-control study in Alberta (Canada) from 2002 to 2006. Participants completed in-person interviews, were assessed for anthropometric measures, and provided 8-h fasting blood samples either preoperatively or postoperatively. Blood was analyzed for the concentrations of TNF-α, IL-6, and CRP by immunoassay. Endometrial cancer cases had consistently higher mean levels of TNF-α, IL-6, and CRP compared with controls in these predominantly postmenopausal women. After adjusting for age, all markers were associated with statistically significant increased risks for endometrial cancer; however, after multivariable adjustment, only the risk from CRP remained elevated (odds ratio=1.22, 95% confidence interval: 1.02-1.47). Similarly, upon stratification by cancer type, only CRP was associated positively with an increased risk for type I endometrial cancer (odds ratio=1.25, 95% confidence interval: 1.03-1.52). All markers were associated with an elevated risk for the more rare and aggressive type II cancers; however, these findings were statistically nonsignificant, likely because of the small number of cases in this group. In conclusion, we found epidemiologic evidence for an association between CRP and the risk of endometrial cancer, which was slightly stronger for type I cancer. No associations emerged for TNF-α and IL-6.
    European journal of cancer prevention: the official journal of the European Cancer Prevention Organisation (ECP) 07/2013; 22(4):374-379. · 2.21 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: C-reactive protein (CRP), a marker of low-grade inflammation, has been associated with breast cancer risk, but results are scarce and inconsistent. A case-control study nested within the E3N prospective cohort included 549 postmenopausal breast cancer cases and 1,040 matched controls, all free of breast cancer at baseline. Serum levels of CRP were measured in samples collected between 1995 and 1999. Unconditional logistic regression models were used to evaluate the association between CRP and breast cancer risk, adjusting for matching factors and known breast cancer risk factors. No association was observed between CRP levels and breast cancer risk overall. However, a significant interaction was observed between CRP levels and body mass index (BMI). A statistically significant increase in breast cancer risk was observed in overweight and obese women (BMI ≥ 25 kg/m(2)) (OR 1.92, 95 % CI 1.20-3.08 for CRP ≥ 2.5 mg/L compared with CRP < 1.5 mg/l, p trend = 0.003, p interaction between CRP and BMI = 0.03). Similar results were observed in women with waist circumference (WC) ≥ 88 cm (p trend = 0.01, p interaction = 0.06) and waist-to-hip ratio (WHR) ≥ 0.80 (p trend = 0.06, p interaction = 0.35). CRP levels were not associated with breast cancer risk in women with normal BMI, WC, or WHR. We found a positive association between CRP levels and postmenopausal breast cancer risk restricted to women with excess adiposity. The suggested relationship between low-grade inflammation, abdominal adiposity, and postmenopausal breast cancer risk deserves further investigation.
    Cancer Causes and Control 02/2014; · 3.20 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Obesity has reached epidemic proportions and is recognized as a major cause of cancer worldwide (World Health Organization 2000, 2011). Obesity can be defined as an excess of body adiposity, which is evaluated according to the body weight. The body mass index (BMI) correlates weight and height (BMI = weight in kilograms divided by the square of the height in meters [kg/m2 ]), and since 1980, BMI has been considered the standard measure for evaluating whether a person is obese. In general, an individual with a BMI between 25 and 30 is classified as overweight or pre-obese, while an individual with a BMI over 30 is classified as obese; different intervals are established according to the mortality risk (Table 2.1) (Caballero 2007; World Health Organization 2000). Although data from the United States indicate that the incidence of obesity is increasing slowly or leveling off when compared to the past decade (Flegal et al. 2010, 2012), more than 1 billion people worldwide are overweight or obese (Deitel 2003). It has been estimated that 14% and 20% of all cancer deaths in men and women, respectively, can be attributed to excess body weight (Calle et al. 2003, 2004; Wolin et al. 2010). Obesity is associated with some types of cancer (Simard et al. 2012), such as colon, breast (postmenopausal), endometrial, kidney (renal cell), esophageal (adenocarcinoma), pancreatic, colorectal, and, potentially, gall bladder carcinoma (Wiseman 2008; Vainio et al. 2002). In addition...
    08/2013; , ISBN: 9781466503700

Full-text (2 Sources)

Available from
Jun 5, 2014